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Background: Clinical staging of mental disorders proposes that individuals can be assessed at various sub-syndromal
and later developed phases of illness. As an adjunctive rating, it may complement traditional diagnostic silo-based
approaches. In this study, we sought to determine the relationships between clinical stage and neuropsychological
profile in young persons presenting to youth-focused mental health services.
Methods: Neuropsychological testing of 194 help-seeking young people (mean age 22.6 years, 52% female) and 50
healthy controls. Clinical staging rated 94 persons as having an ‘attenuated syndrome’ (stage 1b) and 100 with a
discrete or persistent disorder (stage 2/3).
Results: The discrete disorder group (stage 2/3) showed the most impaired neuropsychological profile, with the earlier
stage (1b) group showing an intermediate profile, compared to controls. Greatest impairments were seen in verbal
memory and executive functioning. To address potential confounds created by ‘diagnosis’, profiles for those with a
mood syndrome or disorder but not psychosis were also examined and the neuropsychological impairments for the
stage 2/3 group remained.
Conclusions: The degree of neuropsychological impairment in young persons with mental disorders appears to
discriminate those with attenuated syndromes from those with a discrete disorder, independent of diagnostic status
and current symptoms. Our findings suggest that neuropsychological assessment is a critical aspect of clinical
evaluation of young patients at the early stages of a major psychiatric illness.
Keywords: Neuropsychology, Clinical staging, Psychiatric, Young adultsBackground
There is recognition of the need for new clinical and
research frameworks to enhance earlier intervention in
young people with emerging major mental disorders
(McGorry et al. 2009, 2006; Fava et al. 2012; Hickie et al.
2013a; Cosci and Fava 2013). To this end, the potential
value of adapting clinical staging has been increasingly
recognised (McGorry et al. 2006; Hickie et al. 2013b).
These processes propose that it is possible to differentiate
prodromal, sub-syndromal or ‘at-risk’ states from first
major, acute or recurrent episodes, largely independent
of diagnostic considerations. To date, the utility of* Correspondence: daniel.hermens@sydney.edu.au
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reproduction in any medium, provided the orclinical staging has been tested largely within those who
present with psychotic symptoms. However, most young
people who present for care with early but disabling
forms of mental disorder have admixtures of anxiety,
depressive or brief hypomanic or psychotic symptoms
and are at risk of developing a broad range of adverse
psychological, physical health and functional outcomes.
For these individuals, we do not have diagnostic or
predictive strategies to guide treatment selection or more
individualised clinical practice.
Broader staging models have now been proposed for
those young people who present with psychotic symptoms
or features suggestive of a major mood disorder (McGorry
et al. 2006; Hetrick et al. 2008). More recently, we have
presented a detailed methodology (Hickie et al. 2013a) foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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et al. (2006) for use in young people presenting with
psychotic or mood syndromes. This latest version offers a
more refined rating system, particularly with regards
to stage 3 [see (Hickie et al. 2013a)]. Subsequently,
we have conducted a number of key studies evaluat-
ing the relationships between these proposed early and
later clinical stages and a range of potential biomarkers in-
cluding structural brain imaging (Lagopoulos et al.
2012) and circadian parameters (Naismith et al. 2012). As
cognitive impairment is one of the characteristic features
of major mental disorders and as it can be reliably and ob-
jectively measured by formal neuropsychological testing, it
represents one of the most important potential validators
of our novel clinical staging framework. In this first report
of a large cohort of young people, we test the proposition
that different stages of illness (as an adjunctive rating
to the traditional diagnostic categories) are associated
with differential patterns of neuropsychological
impairment.
Methods
The study and consent procedure was approved by the
University of Sydney Human Research Ethics Committee.
All participants were determined by their referring
clinician or mental health professional to have the mental
and intellectual capacity to give written informed consent
prior to participation in the study.Participants
One hundred and ninety four young people were
recruited from specialised ambulatory care services
(Youth Mental Health Clinic at the Brain & Mind
Research Institute; and headspace, Campbelltown,
Sydney, Australia (Scott et al. 2009; Scott et al. 2012))
for the assessment and early intervention of mental
health problems. Importantly, the key inclusion criterion
for this study were: (i) persons aged 18 to 30 years
seeking professional help primarily for a depressive
(unipolar or bipolar) and/or psychotic syndrome; and, (ii)
willingness to participate in longitudinal research related
to clinical and neurobiological outcomes (Lagopoulos
et al. 2012; Hermens et al. 2011). Participants were asked
to abstain from drug and alcohol use for 48 hours prior
to testing.
Participants were excluded if they had insufficient fluency
in the English language to participate in the neuropsycho-
logical assessment, were intellectually impaired (e.g.
IQ < 70) or had current substance dependence. Comorbid
or pre-existing childhood-onset conditions, such as ADHD
and conduct disorder, as well as anxiety, alcohol or other
substance misuse or autistic spectrum disorders were not
exclusion criteria.Clinical staging
Our clinical staging model (Hickie et al. 2013a) builds
on routine clinical assessment (though it may be assisted
by ancillary investigations). Typically, a clinical stage
is formally assigned at the end of the assessment
phase. Such clinical assessment captures: (i) current
major symptoms (severity, frequency, type); (ii) char-
acteristic mental features; (iii) age of onset and clin-
ical course of illness prior to presentation; (iv) previous
“worst ever” symptoms and treatments including hospital
admissions; (v) current level of risks of harm due to
illness; (vi) previous suicide attempts or other at-risk
behaviours; and, (vii) current (as compared with premor-
bid) levels of social, educational or employment function-
ing. Once this information is obtained and integrated, a
clinical stage is then assigned according to sets of
established criteria [see (Hickie et al. 2013a)]. It should be
noted that in the most recent version of our model we
stipulate that supporting instrumentation (e.g. socio-
occupational and symptom rating scales) should be used
as a guide and not as an absolute cut-off to determine
stage. Similarly, biomarkers (i.e. from neuroimaging and
neuropsychology) are subject to empirical research and
are therefore not part of the stage assignation process.
As described in detail elsewhere (Hickie et al. 2013a),
our staging model includes five discrete categories: stage
1a = ‘help-seeking’; stage 1b = ‘attenuated syndrome’;
stage 2 = ‘discrete disorder’; stage 3 = ‘recurrent or
persistent disorder’; and stage 4 = ‘severe, persistent and
unremitting illness’. Importantly, entry to stage 2 is not
simply analogous to, or defined by, meeting existing
DSM or ICD criteria for a specific mood or psychotic
disorder (the stage rating is adjunctive to the assignation
of traditional DSM or ICD diagnoses). However, a key
point of differentiation (and the focus of this study) occurs
between the ‘attenuated syndrome’ stage (1b) and the
onset of a more discrete disorder (stage 2). Thus only
patients who were consensus rated at stage 1b, 2 or
3 by two senior psychiatrists (EMS and IBH) were
included in this study. Stage 1b is assigned when the
individual has developed specific symptoms of severe
anxiety (including specific avoidant behaviour), moderate
depression (associated with persistently depressed mood,
anhedonia, suicidal ideation or thoughts of self-harm and/
or some neurovegetative features), brief hypomania (less
than 4 days duration during any specific episode) and/or
brief psychotic phenomena (of brief duration only). Stage
2 is assigned when the individual displays a psychotic
(i.e. a clear psychotic syndrome for more than a week),
manic (i.e. manic syndrome (not just symptoms) for more
than 4 days during a specific illness event) and/or severe
depressive (i.e. psychomotor retardation, agitation, impaired
cognitive function, severe circadian dysfunction, psychotic
features, brief hypomanic periods, severe neurovegetative
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episode. An individual with an anxiety disorder would be
assigned to stage 2 if they have a concurrent, moderately
severe depressive disorder, typically associated with marked
agitation, fixed irrational beliefs, overvalued ideas or
attenuated psychotic symptoms, or substantial and persistent
substance misuse. Stage 3 is met if the discrete disorder
persists over 12 months with poor or incomplete response
to a reasonable course of treatment (i.e. of 3 months
duration). Individuals who relapse to the full extent
described in stage 2 are also assigned to stage 3. For
details regarding the mixed syndromes and comorbid fea-
tures within each stage assignation see (Hickie et al. 2013a).
A total of 194 patients were rated as stage 1b (n = 94),
stage 2 (n = 69), or stage 3 (n = 31). In keeping with our
previous research (Naismith et al. 2012; Lagopoulos et al.
2012) the last two stage-groups were combined (i.e. ‘stage
2/3’). The primary DSM-IV (APA 2000) diagnoses for
those in stage 2/3 (n = 100) were as follows: n = 18
with a major depressive disorder; n = 25 with a bipolar
disorder [bipolar I (n = 9); bipolar II (n = 16)] and n = 57
were diagnosed with a psychotic disorder [first-episode
psychosis (n = 28); schizoaffective disorder (n = 11);
schizophrenia (n = 17); psychotic disorder not otherwise
specified (n = 1)].
Clinical assessment
A trained research psychologist conducted a structured
clinical interview to determine the nature and history of
any mental health problems. Our ‘BMRI Structured
Interview for Neurobiological Studies’ (Scott et al. 2013;
Lee et al. 2013) initially obtains key demographic and
clinical information, focussing on critical illness course
variables (e.g. onset of symptoms, number of depressive,
manic or psychotic episodes, hospitalisation, etc.). As a
proxy measure for duration of illness, the age that each
patient first engaged a mental health service was
recorded. The interview then utilises established clinical
scales including the 24-item Brief Psychiatric Rating
Scale (BPRS) (Dingemans et al. 2013) and the 17-item
Hamilton Depression Rating Scale (HDRS) (Hamilton
1967) to quantify general psychiatric and depressive
symptoms at the time of assessment. The social and
occupational functioning assessment scale (SOFAS)
(Goldman et al. 1992) was also used as a rating of the
patient’s functioning from 0 to 100, with lower scores
indicating more severe impairment. Patients also completed
self-report questionnaires that included the 10-item Kessler
Psychological Distress Scale (K-10) (Kessler et al. 2002)
to detect psychological distress.
Neuropsychological assessment
Pre-morbid intelligence (‘predicted IQ’) was estimated
on the basis of performance on the Wechsler Test ofAdult Reading (Wechsler 2001). ‘Psychomotor speed’
was assessed using the Trail-Making Test (TMT), part A
(TMT-A), with ‘mental flexibility’ assessed by part B
(TMT-B) (Strauss et al. 2006). ‘Verbal learning’ and
‘verbal memory’ were assessed by the Rey Auditory Verbal
Learning Test (RAVLT) (Strauss et al. 2006) sum of trial
1–5 (RAVLT sum) and 20-minute delayed recall (RAVLT
A7) respectively. Finally, ‘verbal fluency’ was assessed
by the letters subtest of the Controlled Oral Word
Association Test (COWAT FAS) (Strauss et al. 2006).
Participants also completed subtests from the Cambridge
Neuropsychological Test Automated Battery (CANTAB)
(Sahakian and Owen 1992). The CANTAB tests have the
advantage of being largely non-verbal (i.e. language-
independent, culture-free) and have been described in
detail elsewhere (Sahakian and Owen 1992; Sweeney et al.
2000; Hermens et al. 2011). Four tasks were included for
analysis in the current study: ‘sustained attention’, as
indexed by the A prime (sensitivity to the target) measure
of the Rapid Visual Information Processing task (RVP A),
‘working memory’ as indexed by the total span length
from the Spatial Span task (SSP); ‘visuo-spatial learning
and memory’ as indexed by the total adjusted errors score
from the Paired Associate Learning task (PAL) and ‘set
shifting’ was indexed by the total adjusted errors score
from the Intra-Extra Dimensional task (IED errors).Statistical analyses
To control for the effects of age, neuropsychological
variables were converted to ‘demographically corrected’
standardised scores (z-scores) using the following established
norms: TMT (Tombaugh et al. 1998b); RAVLT (Rickert
and Senior 1998); and COWAT FAS (Tombaugh et al.
1998a). Similarly, CANTAB z-scores, based on an internal
normative database of the 3000 healthy volunteers (http://
www.camcog.com), were calculated for each participant.
Prior to analyses, outliers beyond ± 3.0 z-scores for
each neuropsychological variable were curtailed to
values of +3.0 or −3.0. There were no more than 7%
of cases in any group with a z-score of beyond ±3.0
across variables. Differences in demographic, clinical
and neuropsychological measures across the three groups
were assessed using one-way ANOVA. Levene’s test was
used to test for homogeneity of variance; Welch’s statistic
was calculated, with corrected df and p-values reported
where this assumption was violated. Scheffé’s tests were
used to determine post-hoc pair-wise comparisons with
the control group. Chi-squared test was used to compare
the ratio of females to males across groups. Pearson’s
correlations were used to test association between clinical
and neuropsychological variables for patients only. Statis-
tical analyses were performed using SPSS for Windows
20.0 and all significance levels were set at p<0.05.
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As shown in Table 1, there were no differences amoung
the three groups (i.e. Stage 1b, stage 2/3 and controls) in
terms of their current age or predicted IQ. There was
however a significant difference (p<.05) in the distribution
of gender across the groups with the stage 2/3 group have
the lowest proportion of females (43%) compared to the
stage 1b group with the highest proportion (62%). There
was also a significant main effect of group (p<.001) for
years of education; post-hoc Scheffe’s tests confirmed that
this was due to the controls having more formal education
(at 14.8 ± 2.2 yrs) than the two patients groups – who
did not differ from each other (see Table 1). There were
similar, and somewhat expected, findings for the clinical
measures. Social functioning (SOFAS), current depressive
(HDRS) and general psychiatric (BPRS) symptoms as well
as self-reported psychological distress (K-10) all showed a
significant main effect at the group level (p<.001). This
was primarily due to the controls being non-symptomatic
(as expected), whereas the patient groups did not differ
from each other aside from their SOFAS scores where the
stage 2/3 group was rated lower than their stage 1b peers,
by approximately 5 points (out of 100).
The neuropsychological profiles (mean z-scores) for all
three groups are depicted in Figure 1 and the corresponding
ANOVAs and post-hoc tests are summarised in Table 2.
With the exception of verbal fluency (COWAT FAS), the
control group showed a normal profile of neuropsycho-
logical function with all variables averaging between 0.0
and 0.5 standardised scores. In contrast, the stage 2/3
group showed the worst profile with neuropsychological
z-scores ranging between 0.0 and −1.0; the stage 1b
group showed an intermediate profile (see Figure 1).
The differences in these three profiles was confirmed by
the ANOVA’s which showed a significant (at least p<.05)
main effect of group for all but one variable. The lack of a








Females, n (%) 58 (62%) 43 (43%) 29 (58%)
Age, years 22.2 ± 3.2 23.0 ± 3.3 23.0 ± 2.7
Age of onset, years 15.4 ± 3.3 17.6 ± 4.9 n/a
Predicted IQ 103.0 ± 8.5 103.2 ± 10.8 106.0 ± 7.8
Education, years 12.8 ± 2.1 13.1 ± 2.4 14.8 ± 2.2
SOFAS 61.4 ± 11.3 56.4 ± 12.5 92.0 ± 3.2
HDRS total 12.9 ± 6.5 12.5 ± 8.5 2.0 ± 2.2
BPRS total 40.5 ± 9.6 42.7 ± 12.3 26.5 ± 2.7
K10 total 28.1 ± 7.7 26.0 ± 9.1 15.4 ± 5.1
Note: Significance levels for each Scheffé’s post-hoc comparison are depicted by: **differences in the premorbid IQ measure (which is based
on a verbal IQ score). Post-hoc Scheffe’s tests revealed
that for the remaining eight neuropsychological variables
(i.e. not including verbal fluency) the stage 2/3 group
performed significantly worse than controls. As compared
to the stage 1b group, stage 2 patients were worse on three
variables: verbal learning (RAVLT sum), verbal memory
(RAVLT A7) and set-shifting (IED errors). Interestingly,
for the remaining five variables, the stage 1b group was
significantly worse than controls but no different (statisti-
cally) to the stage 2 group (see final three columns in
Table 2). Follow-up ANCOVAs revealed that all of the
eight neuropsychological variables remained significant
after controlling for gender.
As shown in Table 3, the proportion of patients who
were currently medicated with an anti-depressant was
comparable in the stage 1b (54%) and stage 2/3 (45%)
groups. However, there were three times more cases in
stage 2/3 who were currently taking an anti-psychotic
and/or a mood stabiliser; whereas stage 1b patients were
six times more likely to not be taking a major psychotropic
medication at the time of testing (see Table 3). While
there were no significant associations between the symptom
measures (HDRS; BPRS) and neuropsychological variables
for the entire patient sample, there were significant Pearson’s
correlations for the stage 1b group only. These patients
(stage 1b) showed a significant negative correlation be-
tween TMT-B and both HDRS total [r(91)= −0.30, p<.01]
and BPRS total [r(90)= −0.28, p<.01] scores. Similarly, the
stage 1b groups showed significant correlations between
RVP A and both HDRS total [r(78)= −0.23, p<.05] and
BPRS total [r(77)= −0.28, p<.05] scores. In all correlations,
poorer performance was associated with worse symptoms.
Of note, the stage 2/3 group showed no significant
correlations between these variables.
In order to address potential confounds created by




1b v 2/3 1b v Ctrl 2/3 v Ctrl
χ2 (2, 244) = 7.4 [.025]
F (2, 243) = 2.2 [.118]
F (1, 160.8) = 12.7 [.000]
F (2, 242) = 1.9 [.148]
F (2, 243) = 13.7 [.000] *** ***
F (2, 143.9) = 557.5 [.000] ** *** ***
F (2, 150.2) = 149.6 [.000] *** ***
F (2, 147.4) = 146.2 [.000] *** ***
F (2, 135.5) = 72.4 [.000] *** ***























































































































































Stage 1b Stage 2/3 Control 
Figure 1 Profile of z-scores (with standard error bars) for neuropsychological measures across the stage 1b (n = 94), stage 2/3
(n = 100) and control (n = 50) groups.
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were also examined. Figure 2 shows the neuropsychological
profiles for subsamples of the stage 1b (N = 79) and stage
2/3 (N = 41) patients. As compared to the same control
group, these subsamples show very similar profiles as seen
in the stage-groups which included patients with psychosis
with significant (p<.05) main effects of group for five
neuropsychological variables (RVP A; RAVLT sum; RAVLT
A7; PAL errors and TMT-B). While the magnitude of







TMT A 0.02 ± 1.04 −0.08 ± 1.03 0.45 ± 0.79
RVP A −0.52 ± 1.34 −0.74 ± 1.27 0.08 ± 1.05
RAVLT sum −0.20 ± 1.12 −0.79 ± 1.30 0.16 ± 0.76
RAVLT A7 −0.15 ± 1.23 −0.92 ± 1.40 0.24 ± 0.81
SSP −0.07 ± 1.18 −0.08 ± 1.11 0.47 ± 1.13
PAL errors −0.18 ± 1.05 −0.54 ± 1.25 0.33 ± 0.61
IED errors 0.01 ± 0.82 −0.64 ± 1.21 0.01 ± 1.08
TMT B −0.38 ± 1.29 −0.52 ± 1.28 0.22 ± 1.12
COWAT (FAS) −0.17 ± 0.99 −0.49 ± 1.04 −0.32 ± 0.14
Note: Significance levels for each Scheffe post-hoc comparison are depicted by: ***verbal learning (RAVLT sum), verbal memory (RAVLT A7)
and visual memory (PAL errors) remained significantly
(p<.05) worse than controls. Whereas the stage 1b group
only differed significantly (p<.05) from controls in RVP A
(see Figure 2).
Discussion
This study identified distinct neuropsychological profiles
that distinguished those young people with ‘attenuated




1b v 2/3 1b v Ctrl 2/3 v Ctrl
F (2, 140.2) = 6.5 [.002] * *
F (2, 210) = 6.6 [.002] * **
F (2, 148.6) = 15.9 [.000] ** ***
F (2, 148.2) = 20.3 [.000] *** ***
F (2, 217) = 4.2 [.017] * ***
F (2, 141.8) = 16.0 [.000] * ***
F (2, 116.3) = 9.3 [.000] *** **
F (2, 230) = 5.8 [.004] * **
F (2, 230) = 2.4 [.091]
= p<.001; ** = p<.01; * = p<.05.
Table 3 Cross-tabulation of stage group by medication
category
Current Medication Stage 1b (n = 94) Stage 2/3 (n = 100)
NIL Count 25 4
% 27% 4%
Any Anti-Depressant Count 51 44
% 54% 44%
Any Anti-Psychotic Count 26 78
% 28% 78%
Any Mood Stabiliser Count 7 25
% 7% 25%
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As expected, those in the later stages showed the most
impaired neuropsychological profile with the attenuated
syndrome patients showing an intermediate profile com-
pared to controls (as well as the standardised ‘norm’).
These neuropsychological findings are especially important
given the lack of differences between the patient groups
in terms of their overall current symptoms and levels of
distress. These findings provide further important validation
of our clinical staging model, particularly with respect to the
notion that the change from stage 1b to stage 2 and 3 repre-










































































Stage 1b (mood) 
Figure 2 Profile of z-scores (with standard error bars) for neuropsych
stage 1b (n = 79) and stage 2/3 (n = 41), versus control (n = 50) grouThe findings presented here are consistent with our
other studies showing a similar demarcation in both
neuroimaging (Lagopoulos et al. 2012) and circadian
(Naismith et al. 2012) measures. In the former study, there
were frontal grey matter volume differences between
the stage 1b and stage 2/3 groups, suggesting a major
transition point (Lagopoulos et al. 2012). In the latter
study, stage 2/3 patients, but not stage 1b patients,
showed a disruption in a circadian system marker (reduced
melatonin secretion) which was associated with less
subjective sleepiness and poorer performance in a memory
task (Naismith et al. 2012). In relation to neuropsycho-
logical profiles, there is very little other literature to
compare our results to. While numerous studies have
described the neuropsychological profiles of prodromal or
‘ultra-high risk’ states for psychosis there are, to our
knowledge, no studies that have included young patients
with unipolar and/or bipolar illnesses. This may be a
critical oversight, given evidence that affective and psychotic
disorders probably represent different combinations of the
same continuously distributed dimensions of symptoms,
particularly at early stages (Hafner et al. 2008). Importantly,
our clinical staging model (Hickie et al. 2013a) maintains
that there is inherent heterogeneity of cases within each
clinical stage and that more detailed profiling (using












































































Stage 2/3 (mood) Control 
ological measures across the mood syndrome/disorder subset at
ps.
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that cause patients to express a discrete disorder or
not (that is, despite being similar in age and current
symptomatology).
Our samples are representative of young help-seeking
outpatients with admixtures of depressive, (hypo)manic
and psychotic symptoms. However, there is some evidence
to suggest that those with psychotic spectrum illness show
the most marked neuropsychological impairments at
various ages (Quraishi and Frangou 2002). Therefore we
also examined the neuropsychological profiles of only
those with a mood syndrome or disorder and our results
confirm that such patients showed a similar overall pattern
as the larger sample (with psychosis included), albeit to a
lesser degree. Critically, the two key neuropsychological
variables (i.e. verbal memory and set-shifting, an aspect of
executive functioning) remained significantly different
across the clinical-stage groups (and markedly reduced
in the stage 2/3 patients). Separate lines of research have
shown that cognitive decline in the form of verbal memory
and executive function deficits is characteristic of (and
often precedes) the early stages of both affective (Burt
et al. 1995) and psychotic (Brewer et al. 2005; Seidman
et al. 2010) disorders. Similarly, there are several studies
showing that impaired neuropsychological function
(particularly with regards to memory and executive
function) in early stage young patients with mental disorders
predicts longer-term poor (typically functional) outcomes
(Bodnar et al. 2008; Seidman et al. 2010). Thus, it is
becoming increasingly important to identify the best
neuropsychological markers for early intervention. This is
particularly warranted given that pharmacological (e.g. anti-
depressant) (Sheline et al. 2003) and non-pharmacological
(e.g. cognitive training) (Naismith et al. 2010) strategies
may offer neuroprotection against further cognitive
damage (Simon et al. 2007).
This study has limitations. Firstly, the cross-sectional
design impacts any conclusions about which neuro-
psychological variables reflect trait versus state aspects of
these stages of illness. The presence of some significant
associations between the sustained attention or cognitive
flexibility measures and current depressive or general
psychiatric symptoms (in the stage 1b group) suggests
that at least some aspects of executive functioning may be
modulated by an individuals state. Clearly longitudinal
studies would provide very important information about
such trait versus state aspects. Secondly, we did not
control for any potential effects of psychotropic medication.
Although we opted to assess these young patients under
‘treatment as usual’ conditions, the real impact that
such medications have on neuropsychological function
is unknown. Given the early stage of illness it is unlikely
that the current medications afforded any neuroprotection,
but rather offered some amelioration of affective and/orpsychotic symptoms. While the clinical-stage groups did
not differ in the prevalence of current antidepressant
treatment there were differences in the frequency of
antipsychotics and mood stabilisers. While there is
good evidence to show that the former have very little
direct effects on cognition, particularly at early stages
in the course of treatment, there is less known about
these effects from the latter. Thirdly, the control group
in this study were more educated than the patient
groups. Despite this, all three groups were matched in
their predicted IQ and the standardised scores for each
neuropsychological variable were adjusted for age and
years of education. Fourthly, while the lack of a signifi-
cant difference in age among groups was helpful in
evaluating the differences in neuropsychological function
it may also limit the generalizability of our findings. In our
previous study (Scott et al. 2012), utilising a much larger
(N = 1260), albeit younger (i.e. 12 to 25 years of age)
sample of patients (accessing the same services as
those in the current study), we reported age differ-
ences among the three stage groups (stage 1b = 17.4 ±
3.4 years; stage 2 = 18.7 ± 3.2 years; stage 3 = 20.3 ±
3.4 years). Given the different age range in the current
study (in particular the minimum age of 18 years)
these findings may only represent young adults at
various stages of illness; future studies should include
younger patients (despite the limitations in normative
data and valid neuropsychological subtests for younger
subjects). Another limitation may be the significant
differences among groups in terms of the proportions
of females-to-males. Just over two-thirds (62%) of
those in the stage 1b group were female, compared to
the lower proportion of females (43%) in the stage 2/3
group. These ratios are quite different to those in our
larger, younger cohort (Scott et al. 2012) with 47% and
54% females in stage 1b versus stage 2/3, respectively.
Although our statistical analyses attempted to control
for the effects gender, our findings should be treated
with some caution until future studies with larger
sample sizes (and presumably more equal proportions
of the genders) are conducted. Finally, as highlighted
in a recent systematic review (Cosci and Fava 2013)
there are numerous variations of staging models for
mental disorders. In their distillation of this literature,
Cosci and Fava (2013) propose separate models for a
range of disorders (including schizophrenia, unipolar de-
pression, bipolar and alcohol use disorders). Thus, it is im-
portant to recognise the distinctions between the model
investigated in this current study and others in the
literature. Comprehensive longitudinal research will
help to determine the utility of staging within single
disorders (see (Cosci and Fava 2013)) versus staging
across a range of syndromes (Hickie et al. 2013b;
Hickie et al. 2013a).
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In conclusion, this study is the first of its kind and shows
that there is a neuropsychological point of differentiation
in young persons with an attenuated syndrome as
compared to those with a discrete or persistent disorder.
While those in the latter group show impairments in
memory and executive measures that are consistent
with the literature, the ‘intermediate’ profile seen in
the attenuated syndrome patients suggest that they are on
a similar neuropsychological trajectory despite current
symptoms and, possibly, current treatment. These findings
add strength to our clinical staging model and support
our findings in other neurobiological measures (Naismith
et al. 2012; Lagopoulos et al. 2012). Furthermore, these
findings suggest that neuropsychological assessment is a
critical aspect of clinical evaluation of young patients at
the early stages of a major psychiatric illness.
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